• Cytokinetics stock soars on heart drug data that sets stage for Phase 3 studies

    2 monthes ago - By MedCity News

    A Cytokinetics drug in development for treating a rare heart disorder has promising Phase 2 data suggesting it could compete against a Bristol Myers Squibb drug currently under FDA review. Cytokinetics plans to advance its small molecule to Phase 3 testing by the end of this year.
    Read more ...